investors.xoma.comInvestor Relations :: XOMA Corporation (XOMA)

window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/12.0.0-1\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/12.0.0-1\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/www.xoma.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=5.2.2"}}; !function(a,b,c){function d(a,b){var c=String.fromCharCode;l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,a),0,0);var d=k.toDataURL();l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,b),0,0);var e=k.toDataURL();return d===e}function e(a){var b;if(!l||!l.fillText)return!1;switch(l.textBaseline="top",l.font="600 32px Arial",a){case"flag":return!(b=d([55356,56826,55356,56819],[55356,56826,8203,55356,56819]))&&(b=d([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]),!b);case"emoji":return b=d([55357,56424,55356,57342,8205,55358,56605,8205,55357,56424,55356,57340],[55357,56424,55356,57342,8203,55358,56605,8203,55357,56424,55356,57340]),!b}return!1}function f(a){var c=b.createElement("script");c.src=a,c.defer=c.type="text/javascript",b.getElementsByTagName("head")[0].appendChild(c)}var g,h,i,j,k=b.createElement("canvas"),l=k.getContext&&k.getContext("2d");for(j=Array("flag","emoji"),c.supports={everything:!0,everythingExceptFlag:!0},i=0;i Skip to content Menu About Us Overview Management Team Board of Directors Contact Us Royalty Portfolio Opportunities Overview Royalty Acquisition Assets Available for Licensing Phage Display Platform IL-2 Antibody Anti-prolactin Antibody XMetA Portfolio Anti-PTH1R Antibody News Company & Partner News Press Releases Investors Overview News & Events Financial Information Stock Data Analyst Coverage SEC Filings Governance Contact Menu About Us Overview Management Team Board of Directors Contact Us Royalty Portfolio Opportunities Overview Royalty Acquisition Assets Available for Licensing Phage Display Platform IL-2 Antibody Anti-prolactin Antibody XMetA Portfolio Anti-PTH1R Antibody News Company & Partner News Press Releases Investors Overview News & Events Financial Information Stock Data Analyst Coverage SEC Filings Governance Contact Investor Relations We Are a Biotech Royalty Aggregator With 65-Plus Assets and Growing XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s). Download Presentation Investors Investors Overview News & Events Overview Company & Partner News Press Releases IR Calendar Email Alerts Financial Information Overview Financial Results Income Statement Balance Sheet Cash Flow Stock Data Overview Charts Historical Data IRS Form 8937 Analyst Coverage SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Management Team Board of Directors Board Committees Governance Documents Investor Relations Company & Partner News Dec 05, 2019 Iscalimab Update View Press Release View All News Aug 07, 2019 CEO Letter – First Half 2019 Aug 01, 2019 XOMA Congratulates Rezolute on its Successful Financing and Progress Towards Initiating Phase 2b Study for RZ358 Jun 18, 2019 XOMA Congratulates Sesen Bio on Successful Pre-BLA Meeting with FDA for Vicinium Latest Press Releases Dec 20, 2019 • 4:35 PM EST XOMA Announces Closing of Rights Offering Dec 5, 2019 • 5:04 PM EST Iscalimab (CFZ533) Update Dec 2, 2019 • 4:30 PM EST XOMA Announces Commencement of Rights Offering View All Press Releases Latest Presentation Feb 20, 2020 Corporate Presentation View Presentation Latest Financial Results Q3 2019 Quarter Ended Sep 30, 2019 Earnings Release PDF HTML 10-Q Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing For Fiscal Year Ending Dec 31, 2018 Report Links Annual Report Document Links View 10-K For complete information regarding our financials, see our periodic filings Sign Up For Email Alerts Receive updates straight into your inbox Sign up today Stock Snapshot View Detailed Stock Information Company Overview XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding. View Board of Directors XOMA Corporation at a Glance 65+ Total assets 42 Assets with large-cap partners 11+ Therapeutic categories Our Two-part Royalty-aggregator Business Model Our royalty-aggregator strategic approach allows us to focus on advancing our portfolio assets through investments made by our licensees. Our licensees have assumed the responsibility for subsequent development, regulatory approval, and commercialization. As licensees advance these programs, we are eligible to receive future milestone and royalty payments. View Our Full Pipeline of Assets Part 1: Advancing Our Fully Funded Programs The first component of our business strategy includes advancing our current portfolio of fully funded programs through investments made by our licensees. Our diversified pipeline was built by out-licensing our technology platform and our drug candidate products to licensees or collaborator partners who assumed the responsibilities of later stage development, regulatory approval and commercialization. Since our partners pay the development, and commercialization costs, we, therefore, refer to these programs as “fully funded.” Part 2: Acquiring Milestone and Royalty Licenses The second component of our strategy involves acquiring milestone and royalty licenses to high-potential, fully funded assets from companies, universities, or individuals who seek to monetize the value of their licenses. We believe that by expanding our pipeline through these acquisitions, we can further diversify our pipeline across multiple therapeutic areas and development stages. Our ideal target acquisitions are those that are in pre-commercial stages of development, have an expected long duration of market exclusivity, have high revenue potential, and are partnered with a large pharmaceutical or biopharmaceutical enterprise. Investor Contact Information Company XOMA Corporation 2200 Powell Street Suite 310 Emeryville, CA 94608 Investor Relations T: 510-204-7276 investorrelations@xoma.com Transfer Agent American Stock Transfer & Trust Company, LLC 6201 15th Avenue Brooklyn, NY 11219 T: 718-921-8124 help@astfinancial.com www.astfinancial.com Email Alerts RSS News Feed Terms of Use © 2020 XOMA Corporation. All rights reserved. Any references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug products in development. Follow us: © 2020 XOMA • Powered by GeneratePress Market Data copyright © 2020 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, EOD =End of Day, PD =Previous Day. Market Data powered by QuoteMedia . Terms of Use . Scroll back to top...